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Abstract
The global downregulation of microRNAs (miRNAs) is emerging as a common hallmark of cancer. However, the
mechanisms underlying this phenomenon are not well known. We identified that the oncogenic miR-146b-5p attenuates
miRNA biosynthesis by targeting DICER1 and reducing its expression. DICER1 overexpression inhibited all the miR-146b-
induced aggressive phenotypes in thyroid cells. Systemic injection of an anti-miR-146b in mice with orthotopic thyroid
tumors suppressed tumor growth and recovered DICER1 levels. Notably, DICER1 downregulation promoted proliferation,
migration, invasion, and epithelial-mesenchymal transition through miRNA downregulation. Our analysis of The Cancer
Genome Atlas revealed a general decrease in DICER1 expression in thyroid cancer that was associated with a worse clinical
outcome. Administration of the small-molecule enoxacin to promote DICER1 complex activity reduced tumor
aggressiveness both in vitro and in vivo. Overall, our data confirm DICER1 as a tumor suppressor and show that
oncogenic miR-146b contributes to its downregulation. Moreover, our results highlight a potential therapeutic application of
RNA-based therapies including miRNA inhibitors and restoration of the biogenesis machinery, which may provide
treatments for thyroid and other cancers.
Introduction
MicoRNAs (miRNAs) are short noncoding RNAs that
function post-transcriptionally to suppress gene expression
through interactions of their seed region with com-
plementary sequences in the 3′-untranslated regions (UTRs)
of target messenger RNAs, which consequently affects a
myriad of cellular and developmental pathways [1, 2].
Recently, miRNAs have taken center stage in molecular
oncology due to their participation in the development and
progression of human neoplasms, including thyroid tumors
[3, 4].
Thyroid cancer is the most frequent endocrine malig-
nancy and is the most rapidly increasing of all cancers in the
United States [5]. The classical view of thyroid cancer
pathogenesis considers thyroid carcinomas as tumors
accumulating mutations that drive progression through a
dedifferentiation process initially giving rise to the well-
differentiated carcinomas—papillary (PTC) and follicular
(FTC)—and progressing to poorly differentiated (PDTC)
and undifferentiated or anaplastic (ATC) thyroid carcino-
mas [6]. Activation of oncogenes is a known cause of
miRNA deregulation in thyroid cells. Among the most well-
studied oncogenes that drive malignancy in thyroid tumors
are BRAF, RAS, and RET/PTC, which induce a distinct set
of global changes in the expression of miRNAs [7].
Genomic analysis of PTC tumors in The Cancer Genome
Atlas (TCGA) suggests that miRNA expression patterns
define clinically relevant subclasses and may contribute to
loss of differentiation and tumor progression [3, 8]. Several
studies have shown that miRNA expression is globally
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suppressed in tumor cells [2, 9–11]. However, little is
known about the underlying mechanisms and the pheno-
typic advantages provided to cells by reduced miRNA
expression. Interestingly, in thyroid cancer, differentiated
PTC and FTC present both up- and downregulated
miRNAs, whereas dedifferentiated and aggressive ATC
show almost exclusively downregulated miRNAs, with
various reports describing 44 downregulated miRNAs and
only 6 upregulated miRNAs [12–14]. This suggests that the
progression of differentiated thyroid carcinomas to aggres-
sive ATC is characterized by changes in miRNA expres-
sion, and that miRNA downregulation might play a role in
this transition. Although the mechanism by which miRNAs
are underexpressed in cancer remains unknown, it could
involve the RNAse III-type enzyme DICER1, which plays a
fundamental role in processing miRNA precursors to
mature miRNAs [1]. Generally, lower levels of DICER1
correlate with worse outcomes in lung, breast, skin, endo-
metrial, and ovarian cancer [2]. Also, recurrent somatic
mutations have been detected in metal-binding residues
within the RNase IIIb domain of DICER1, decreasing the
expression of some tumor-suppressive miRNAs, which
likely helps to explain the selective pressures that give rise
to this specific spectrum of mutations in several cancer
types [2], including thyroid cancer [8, 15, 16]. Some
germline mutations in DICER1 are also found in different
types of inherited tumors, leading to an increased predis-
position to differentiated thyroid carcinoma (PTC or FTC)
[16–19]. However, the precise role that DICER1 plays in
thyroid tumor progression is not clear.
Important insights into the potential role of Dicer1 in
tumorigenesis have been provided by its conditional dele-
tion in thyroid follicular cells during mouse development
[20, 21]. These mice were hypothyroid at birth, and pre-
sented loss of thyroid follicular structure with down-
regulation of differentiation markers [20], or showed
characteristics of neoplastic transformation in the thyroid
tissue at adult stages [21]. These findings suggest that
miRNAs are necessary to maintain thyroid tissue home-
ostasis and that Dicer1 could be involved in thyroid
tumorigenesis.
Despite their impact on cancer biology, miRNA-based
cancer therapy is still in its early stages, and almost no studies
have addressed thyroid cancer. We recently described that
intratumoral administration of a synthetic anti-miRNA inhi-
biting miR-146b blocked tumor growth of human thyroid
tumor xenografts [22]. Strategies to restore global miRNA
expression would be a welcome addition to the current ther-
apeutic arsenal for thyroid cancer. In this respect, the small-
molecule enoxacin, which promotes miRNA processing in a
TRBP-dependent manner [23], was shown to have cancer
growth inhibitory effects [24], although none of these studies
were performed in thyroid cancer.
With this information, we aimed to study the function and
regulation of DICER1 in thyroid cancer, and to test whether
its impaired function resulted in global miRNA down-
regulation contributing to a more aggressive phenotype.
Results
The major upregulated miRNAs in thyroid cancer,
including miR-146-5p, target DICER1, promoting
in vitro cell proliferation, migration and invasion
Recently, a specific miRNA signature of highly differentially
expressed miRNAs has been established in thyroid cancer by
TCGA [8], and in a cohort of patients by our laboratory [25].
Among the top overexpressed miRNAs in our study were
miR-146b-5p, miR-146b-3p, miR-221-3p, miR-222-3p, miR-
21-5p, miR-21-3p, and miR-182-5p. To evaluate the func-
tional relevance of this signature for thyroid cancer outcome,
we examined the downstream critical targets of these
miRNAs using the in silico target screening algorithm miR-
anda. The results of this analysis identified DICER1 as a
putatively shared target of the main miRNAs, potentially
forming a miRNA biogenesis regulatory network. Coin-
cidently, the 3′UTR of DICER1 contained several predicted
binding sites for all of these miRNAs, with high probability
mirSVR scores (Fig. 1a). By contrast, almost none of the
previously described underexpressed miRNAs in thyroid
cancer, such as miR-204, miR-30a, and miR-100 [25], were
predicted to target DICER1 (Fig. 1a). These findings raise the
possibility that some upregulated mature miRNAs act in
concert as negative feedback regulators to control DICER1
expression in thyroid cancer, whereas the downregulated
miRNAs may be indirectly affected. Analysis of TCGA
database using the Cancer Regulome tool showed that the
expression of the most highly upregulated miRNAs in PTC—
miR-146b-5p, miR-146b-3p, miR-21-3p, miR-21-5p, miR-
221-3p, and miR-222-3p—negatively correlated with
DICER1 mRNA levels (Fig. 1a). We validated this result
using a focused small-scale screen by transiently transfecting
each miRNA individually into the thyroid cell line Nthy-ori 3-
1, finding that the protein level of DICER1 was reduced in
each case (Fig. S1a).
miR-146-5b is the top overexpressed miRNA in PTC
[25] with >35-fold-higher expression over normal thyroid
tissue and also with a high representation in the PTC
miRNome [25]. It yielded a reasonable mirSVR score for
the DICER1 3′UTR (−0.1471, position nt 1770) (Fig. S1b)
and there was a good negative correlation (−0.39) to
DICER1 expression in TCGA dataset (Fig. S1c). Moreover,
miR-146b is one of the most extensively studied miRNAs
in this tumor type [25] and appears to be a prognostic factor
for PTC, as it associates with aggressive clinicopathological
Impaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness 5487
features and poor clinical outcome [26]. We recently iden-
tified PTEN and CDH1 as miR-146b targets [22]; however,
the full impact and relevance of this particular miRNA as an
oncogenic player has not been explored in depth. Thus, we
focused our attention on this miRNA and evaluated other
downstream targets that may explain its oncogenic features.
We first corroborated that DICER1 is a bona fide target of
miR-146b by analyzing its expression in normal human
thyroid follicular Nthy-ori 3-1 cells stably overexpressing
miR-146b (Nthy-ori-146b) or a control vector (Nthy-ori-
Null). Results showed that DICER1 mRNA and protein levels



































































































miR 3'UTR position mirSV R score fc normal vs. PTC  DICER1 correlation (TCGA)
hsa-miR-146b-5p 1770 -0.1471 35.9 -0.39
hsa-miR-146b-3p - - 33.0 -0.39
hsa-miR-221-3p 919; 207 7 -0.0501; -0.1778 9.4 -0.30
hsa-miR-222-3p 818; 2418 ; 321 5 -0.0226; -0.0086; -0.0368 8.6 -0.34
hsa-miR-21-5p 493; 176 7 -0.0457; -0.0005 3.8 -0.48
hsa-miR-21-3p 3315 -0.0001 3.6 -0.39
hsa-miR-182-5p 189 -0.8132 3.0 n.s
hsa-miR-204-5p - - 0.15 0.41
hsa-miR-30a-3p - - 0.55 0.36
hsa-miR-100-5p - - 0.58 n.s
7017
Fig. 1 miR-146b directly targets DICER1, which in turn blocks
miR-146b-induced proliferation, migration and invasion. a Table
shows the main up- and downregulated miRNAs in thyroid cancer
[25] and their predicted binding sites in the DICER 3′UTR (position
and the mirSVR score for the miRs predicted by miRanda). Also
shown is the fold change (FC) of normal vs PTC and the correlations
between DICER1 and miRNAs using Cancer Regulome analysis in
TCGA database. b, c Stable cell lines were generated from Nthy-ori
cells transfected with a pEGP-Null vector (Null cells) or a pEGP-miR-
146b vector (146b cells). b Left: relative DICER1 expression by
qPCR. Right: immunoblot of DICER1 expression (results are repre-
sentative of 3 experiments). c Direct targeting of DICER1 3′UTR by
miR-146b. Luciferase reporter activity relative to Renilla level was
evaluated in cells 72 h after transfection of pIS1 DICER1 long UTR
(WT) or DICER1 3′UTR mutated in the miR-146b binding site
(MUT). d Representative images of crystal violet-stained cells 48 h
after transfection with the DICER1 expression vector. e Representa-
tive images of a wound healing assay 0 and 48 h after scratching.
f Relative quantification of the invasive capacity of cells was analyzed
using Matrigel-coated Transwell assays. Left: representative images
of the lower chamber (invading cells). Right: cell invasion relative to
that of “Null” cells. Values represent mean ± SD (n= 3). **p < 0.01;
***p < 0.001; n.s. non-significant.
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consistent with the findings of our focused DICER1-miRNA
target screen (Fig. S1a). Moreover, ectopic miR-146b
expression significantly decreased the activity of a
co-transfected luciferase reporter construct containing the
putative wild-type miR-146b binding region in the DICER1
3′UTR (Fig. 1c). However, non-significant changes were
observed when the 3′UTR DICER1 luciferase construct was
mutated in the predicted binding site for miR-146b (Fig. 1c).
Overall, these data show that miR-146b directly represses
DICER1 expression by targeting its 3′UTR.
Given these results, we investigated the role of DICER1
in the aggressive traits induced by miR-146b over-
expression, finding that overexpression of DICER1 cDNA
partly rescued the miR-146b-induced increase in prolifera-
tion, migration, and invasion (Fig. 1d–f). The finding that
miR-146b overexpression induces a global downregulation
of miRNAs, including important tumor suppressor miRNAs
such as miR-30a-5p, miR-30a-3p, miR-100, and miR-204
(Fig. S1d), suggests that the aggressiveness traits induced
by this miRNA are likely elicited by DICER1 inhibition.
Overall, these results show that the 3′UTR of DICER1
contains putative binding sites for the most highly
overexpressed miRNAs (miR-21-3p, miR-21-5p, miR-221-
3p) and that miR-146-5p directly targets DICER1, mediat-
ing the potential oncogenic effects and aggressiveness of
thyroid cancer cells in vitro.
Neutralization of miR-146b suppresses growth of
established thyroid tumors in vivo and restores
DICER1 expression
We next asked if the continuous repression of DICER1 by
endogenous miR-146b in aggressive thyroid cells is
required for tumor growth in vivo. To test this, we first used
our recently developed heterotopic xenograft model [22], in
which established solid tumors of Cal62 cells were treated
intratumorally with a specific anti-miR-146-5p oligonu-
cleotide inhibitor (Anti-146b) or a control. Tumor growth
was significantly blunted in the anti-miRNA-treated tumors,
as we previously demonstrated [22]. We then analyzed
DICER1 mRNA and protein levels in these xenograft
tumors, finding that intratumoral anti-miRNA treatment
rescued the levels of DICER1 (Fig. 2a–c). This suggests










































































Fig. 2 miR-146b inhibition impairs established human thyroid tumor
growth. a–c Tumor samples taken from mice treated with a control or
an miR-146b inhibitor (Anti-146b) administered intratumorally to
tumor xenografts generated as previously described [22]. Tumors were
analyzed for DICER1 expression by a qPCR, b immunoblotting, and
c immunohistochemistry. Actin was used as a loading control.
d Cal62-luc cells were injected into the right thyroid lobe and an
orthotopic thyroid tumor was generated. Then, a synthetic miR-146b
inhibitor (Anti-146b) or a negative control was administered sys-
temically via the retro-orbital vein. Left: endpoint (day 21) biolumi-
nescent signal of the treated tumors. Right: tumor radiance
quantification at the indicated time points in mice from treatment onset
with the miRNA inhibitor (blue) or the negative control (green).
e Representative immunohistochemistry with an anti-DICER1 anti-
body in orthotopic tumors. Values represent mean ± SEM. *p < 0.05
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inhibition of miR-146b contributes, at least in part, to tumor
growth reduction. To better assess the therapeutic potential
of anti-miR-146b, we generated an orthotopic mouse thyr-
oid tumor model. After tumor establishment (3 weeks), 13
mice were randomized into two groups and were injected
intravenously with anti-miR-146b (n= 8) or an appropriate
control (n= 5). Tumor volume was followed for a further
two weeks. Results showed that tumor growth was
significantly delayed in the anti-miRNA-treated group
(Fig. 2d). Notably, DICER1 expression in the primary
thyroid tumor was higher after systemic anti-miR-146b
treatment (Fig. 2e). We did not observe evident adverse
effect of the systemic anti-miR146b treatment in the studied
parameters, as liver morphology and the levels of serum
glucose were similar in both control and treated mice
(Fig. S2a and b, respectively).
DICER1 plays a critical tumor-suppressive role in
thyroid cancer progression
The expression levels of DICER1 were lower in a panel
of thyroid cancer cells than in the control Nthy-ori cells
(Fig. S3a). To examine the effects of DICER1 on tumor-
specific phenotpyes in vitro, we performed loss-of-function
and gain-of-function studies using the cell lines Cal62 and
TPC1, which have intermediate levels of DICER1, and with
SW1736, which has low levels of DICER1 (Fig. S3a).
Silencing of DICER1 in Cal62 and TPC1 cells resulted
in a significant decrease in the expression of several mature
miRNAs (miR-221-3p, miR-30a-5p, miR-21-5p, miR-
146b-5p, miR-100-5p, and miR-204-5p) (Fig. 3a). As
expected, the expression levels of pre-miRNAs were
essentially stable (Fig. S3b). Moreover, proliferation (by
PCNA immunoblotting, cell viability, and DNA synthesis)
(Fig. 3b–d), and also migration and invasion (Fig. 3e, f),
were all higher in DICER1-silenced cells than in controls.
We also observed that the expression of protein markers
involved in epithelial-mesenchymal transition (EMT) was
altered in DICER1-silenced cells at 72 h post-transfection.
Whereas DICER1 silencing significantly decreased the
mRNA levels of the epithelial protein E-cadherin (CDH1),
it increased the expression of several mesenchymal genes/
proteins, including EYA1, EYA2, fibronectin, SNAIL1,
TWIST1, and ZEB1, in both cell lines (Fig. 3g, h). These
data demonstrate that DICER1 is a critical player in thyroid
tumor progression, confirming that DICER1 knockdown
copies the pro-metastatic phenotypes observed by exogen-
ous miR-146b overexpression.
In contrast to the loss-of-function studies, SW1736 cells
ectopically overexpressing DICER1 showed an expected
induction of several DICER1-dependent mature miRNAs
(Fig. S4a), and proliferation, migration, and invasion were
all significantly decreased together with the corresponding
changes in the EMT markers (Fig. S4b–g). Overall, these
data unequivocally establish a role of DICER1 as a tumor
suppressor in thyroid follicular cells, confirming previous
data demonstrating this tumor suppressor effect in other
tumor types [2, 9–11].
Association between DICER1 expression and worse
clinical outcome in thyroid cancer patients
The clinical relevance of DICER1 repression in thyroid
cancer was analyzed in tumor samples and normal tissues
using data acquired from TCGA FireBrowse portal and the
Morpheus tool. We observed that DICER1 levels were
decreased in several cancer types (Fig. 4a), and thyroid
cancer showed the third greatest change in DICER1
expression overall when compared with normal tissue
(Fig. 4b) (normal tissue n= 59, tumor samples n= 501). Of
note, thyroid metastases (n= 8) exhibited even lower levels
of DICER1 than primary tumor samples or normal tissue
(Fig. 4b), pointing to a role for DICER1 downregulation in
tumor progression. To extend these observations, we sur-
veyed DICER1 mRNA levels in an independent paired
cohort of 7 PTC patients (clinical characteristics are sum-
marized in Table S1), finding that levels were lower in
tumor samples than in contralateral normal thyroid tissue in
most patients (Fig. 4c, left). Globally, we observed a sig-
nificant decrease in DICER1 mRNA levels of ~46% in
these patients (Fig. 4c, right).
To further explore the implications of DICER1 dysre-
gulation in thyroid cancer, we sought to study its correlation
with aggressive clinical features. TCGA data from the
public databases cBioportal and Cancer Regulome indicated
that DICER1 levels were inversely correlated with the risk
of recurrence (Fig. 4d) and with extrathyroidal extension
(Fig. 4e). Moreover, DICER1 was more downregulated in
tumors classified within the miRNA clusters 5 and 6,
described in TCGA as the less-differentiated tumors with
high risk of recurrence (Figure S5a) [3, 8]. Overall, these
data strongly suggest an important role for DICER1 in
thyroid tumor progression.
Because the maturation of most miRNAs is blocked in
the absence of DICER1 [27], we analyzed the global
expression of the miRNAs differentially expressed in
thyroid cancer. Through the analysis of TCGA data, we
found 93 miRNAs differentially expressed between sam-
ples of PTC and normal tissue: whereas 20 miRNAs were
upregulated, as many as 73 were downregulated
approximately ~3.5-fold or more (false discovery rate
[FDR] < 0.01 and fold change [FC] > 2 for upregulated
miRNAs and FC < 0.75 for downregulated miRNAs)
(Fig. S5b). The higher number of downregulated miRNAs
relative to upregulated miRNAs in thyroid tumors sug-
gests an important role of potential tumor-suppressive
5490 J. Ramírez-Moya et al.


















































































































































































































































































































































Fig. 3 DICER1 silencing
increases proliferation,
migration and invasion in vitro.
a–f Cal62 and TPC1 cell lines
were transfected with an siRNA
against DICER1 (siDICER1) or
a control siRNA (siControl) and
analysis was performed 48 h
later. a Relative expression
levels of miRNAs. b
Immunoblot of DICER1 and
proliferating cell nuclear antigen
(PCNA). Actin was used as a
loading control. c Representative
images of crystal violet-stained
cells. d BrdU incorporation
relative to siControl-transfected
cells. e Representative images
from a wound healing assay at 0
and 16 h (Cal62, left) or 0 and
48 h (TPC1, right) after
scratching. f Quantification of
the invasion rates. Left:
representative images of the
lower chamber (invading cells).
Right: cell invasion rates relative
to siControl cells. g, h Cells
were transfected with an siRNA
against DICER1 (siDICER1) or
a control siRNA (siControl).
g Relative mRNA levels assayed
by qRT-PCR of EMT genes
CDH1, EYA1, EYA2, FN, PAI1,
SNAIL1, TWIST1, and ZEB1 72
h after siRNA transfection with
RNAiMAX Lipofectamine.
h Immunoblot for DICER1 and
TWIST1 (left) and DICER1,
ZEB1, and fibronectin (right)
48 h after siRNA transfection.
Actin was used as a loading
control. Values represent mean
± SD (n= 3). *p < 0.05; **p <
0.01; ***p < 0.001























































































































































































































































































Fig. 4 DICER1 is downregulated in human PTC tumors. a DICER1
mRNA expression levels in the indicated cancer types obtained by
Firebrowse analysis of the TCGA database. b Box plot of DICER1
mRNA expression levels in thyroid normal tissue, PTC, and
metastases: data were obtained from the TCGA database (normal vs
tumor p-value < 0.001) (Number of samples: 59 control, 501 primary
solid tumors and 8 metastasis). c Left: relative DICER1 mRNA
levels in 7 PTC patients (contralateral and normal thyroid tissue).
Right: total average of DICER1 mRNA relative levels. d, e Corre-
lation between DICER1 mRNA levels in high, intermediate or low
risk (p-value < 0.001, adjusted p-value < 0.01) (d), or extrathyroid
extension (p-value > 0.001, adjusted p-value= 0.3) (e), by analyzing
the cBioPortal, where the TCGA datasets are deposited. Values
represent mean ± SEM. **p < 0.01
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miRNAs in this cancer type, and are in line with the
findings of DICER1 downregulation.
Individual downregulated miRNAs rescue DICER1-
silencing effects
Our data thus far clearly establish a direct role of DICER1
repression by miR-146-5p and potentially other miRNAs in
PTC. Given its tumor suppressor effect, we next sought to
address further downstream DICER1 effector miRNAs
relevant to this phenotype. We and others recently profiled
repressed miRNAs in PTC with potential tumor suppressor
functions [8, 25], which highlighted miR-30a and miR-100.
These miRNAs are reported to be essential for EMT and the
mesenchymal phenotype by, targeting lysyl oxidase and
promoting SNAIL2 expression [13, 28, 29], and have been
described as tumor suppressors in other cancer types. We
confirmed the tumor suppressor functions of miR-30a and
miR-100 in Cal62 cells, as their individual transfection
decreased proliferation (Fig. S6a, b) and invasion
(Fig. S6c).
To assess whether the effects of DICER1 silencing are
directly attributed to these repressed miRNAs, we restored
miR-30a and miR-100 expression in DICER1-silenced cells
and monitored the resulting phenotype. Indeed, transfection
of miR-30a or miR-100 reversed the DICER1-silenced
phenotypes, and decreased proliferation (Fig. 5a, b),
migration (Fig. 5c) and invasion (Fig. 5d). These results
indicate that inhibition of miRNAs with tumor suppressor
functions, such as the DICER1 effectors miR-30a or miR-
100, is critical for the proliferative and motile properties of
malignant tumoral thyroid cells.
Induction of miRNA processing with enoxacin
decreases cell aggressiveness in vitro and tumor
growth in vivo
Although many studies have investigated the impact of
miRNAs on cancer biology, miRNA-based cancer therapy
is still in its early stages and is mostly limited to targeting a
single miRNA [30, 31]. However, because global down-
regulation of miRNA expression and corresponding
DICER1 repression appears to play a role in thyroid cancer,
restoration of their levels or enhancing miRNA biogenesis
might represent an attractive approach in cancer therapy.
Against this background, we treated Cal62, TPC1 and
SW1736 cells with the small-molecule enoxacin, which
enhances miRNA maturation by binding to TRBP. Con-
sistent with its activity against other types of tumors [24],
the enhancement of DICER1 complex enzymatic activity by
enoxacin resulted in an increase in the expression of all
tested mature miRNAs, including tumor suppressor
miRNAs (Fig. 6a). Also, enoxacin markedly inhibited
proliferation, migration, and invasion in Cal62, TPC1, and





















































































































Fig. 5 Downregulated miR-30a and miR-100 in thyroid cancer block
DICER1-silencing-induced effects. Cal62 cells were silenced for
DICER1 (siDICER1) and co-transfected with miR-30a or miR-100
plasmids. Control cells were transfected with siControl and the empty
DICER1 vector. a Representative images of cells transfected with
siControl, siDICER1, siDICER1+miR-30a, and siDICER+miR-100
at 48 h post-transfection and stained with crystal violet. b BrdU
incorporation. c Representative images from a wound healing assay 0,
14, and 24 h after scratching in the above-mentioned conditions. d
Quantification of invasion capacity was analyzed in Matrigel-coated
Transwells. Left: representative images of the lower chamber (invad-
ing cells). Right: cell invasion relative to siControl cells. Values
represent mean ± SD (n= 3). *p < 0.05; **p < 0.01; ***p < 0.001
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EMT markers (Fig. 6g). By contrast, enoxacin had less
effect on non-transformed thyroid Nthy-ori 3-1 cells, as
shown by a slight decrease in proliferation (Fig. S7a, b), but
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Finally, to translate these in vitro findings to an in vivo
thyroid cancer model, we tested enoxacin in the orthotopic
mouse model of human thyroid cancer. After establishing
the tumors, 15 mice were randomized into two groups: a
test group (n= 8) treated daily by intraperitoneal injection
of enoxacin (15 mg/kg) over 28 days, and a vehicle control
group (n= 7) treated with 5% DMSO in phosphate buffered
saline (PBS). We found that enoxacin significantly dimin-
ished the radiance bioluminescence increase (Fig. 7a left)
and decreased tumor growth (Fig. 7a right). We confirmed
the upregulated expression of critical miRNAs in tumors
from enoxacin-treated mice (Fig. 7b), and the down-
regulation of the EMT markers fibronectin and N-cadherin
and the proliferation marker PCNA (Fig. 7c). The systemic
treatment with the drug did not produce adverse effects in
mice, as demonstrated by the similar levels of glucose in
both groups analyzed (Fig. S2c)
Overall, these data suggest that enoxacin enhances
miRNA production and, consequently, re-establishes
DICER1-miRNA processing, eliciting its antitumor effect.
Discussion
We provide evidence that thyroid cancer cells use global
downregulation of a miRNA sub-network to enhance dis-
ease aggressiveness, including the induction of proliferation
and metastatic capacity. Global downregulation of miRNA
maturation has been described in many tumor types [2, 9–
11, 32] including thyroid cancer, where it has been sug-
gested that distinct miRNA expression patterns can distin-
guish ATC from FTC or PTC [14]. Our results give direct
support for and extend this concept by identifying a
mechanism by which miRNA down-modulation leads to
thyroid tumor progression. We show that the most over-
expressed miRNA in thyroid cancer, miR-146b, targets
DICER1, inhibiting its expression. Furthermore, the 3′UTR
of DICER1 also contains putative binding sites for other
upregulated miRNAs (miR21, -222, -221, -182) in thyroid
cancer (Fig. 8). These results are reinforced by our
exhaustive analysis of TCGA data [8]. We focused our
attention on miR-146b, as we have recently characterized its
oncogenic activity in thyroid cancer [22]. The miR-146b-
DICER1 interaction revealed in this work has profound
consequences for the induction of an aggressive phenotype,
as ectopic DICER1 expression rescues the aggressive phe-
notype induced by miR-146b. Since miR-146b is both
produced by and regulates DICER1, this mutual feedback
relationship allows for a low level of DICER1 in thyroid
cancer but not its complete loss, and thus sufficient DICER1
levels are maintained for cell survival and growth.
Repression of DICER1 is not the only oncogenic action
of miR-146b, as we have demonstrated that it also represses
the tumor suppressor PTEN, leading to an activation of the
oncogenic PI3K/AKT pathway [22]. We believe that acti-
vation of PI3K/AKT together with the global down-
regulation of miRNAs could contribute to a more
aggressive tumor phenotype. In our in vivo studies, anti-
miR-146b treatment suppressed tumor growth and reversed
DICER1 expression. These findings have implications for
the treatment of thyroid cancer suggesting that modulation
of miR-146b by RNA-based therapeutics could be clinically
useful.
Conceptually, some of the present data may seem para-
doxical, as DICER1 is downregulated in thyroid cancer, but
some miRNAs are upregulated. However, it is known that,
among other phenomena, the activation of oncogenes cau-
ses upregulation of specific miRNAs [33]. For example,
conditional activation of BRAFV600E and RET/PTC3 in
normal thyroid cells induces the expression of miR-146b
[34], which can explain the co-existence of a general
miRNA downregulation in tumors with low DICER1 levels
and the upregulation of miR-146b. In addition, other
oncogenic pathways in thyroid cancer have been described
to increase miR-146b levels such as NF-κB [35, 36] or
PI3K/AKT pathways [22]. Another possible explanation for
miRNA upregulation could be gene demethylation. Con-
sistent with this is the result of our analysis of TCGA
database, showing that miR-146b is demethylated in thyroid
cancer and its metastasis (Fig. S8), whereas downregulated
miRNAs have almost no change in methylation levels (not
shown).
The analysis of TGCA data showed an association
between low DICER1 expression and thyroid metastasis,
high risk, and extrathyroidal extensions. Indeed, we con-
firmed low DICER1 mRNA levels in a panel of seven PTC
thyroid tumors. Taken together, these data suggest that,
similar to other tumor types [2, 37, 38], low DICER1 levels
in thyroid cancer are associated with advanced tumor stage
and poor clinical outcome [39]. Moreover, the present work
provides functional evidence that DICER1 acts as a strong
tumor suppressor in thyroid cancer, confirming data in other
tumor types.
Fig. 6 Enoxacin induces miRNA expression and decreases cell pro-
liferation, migration and invasion in vitro. Cal62, TPC1, and SW1736
cell lines where treated with enoxacin or PBS+ 5% DMSO (control)
for 5 days. a Relative expression levels of miR-30a-5p, miR-146b-5p,
miR-221-3p, miR-100-5p, miR-21-5p, miR-30a-3p, and miR-204-5p
in cells. b Immunoblot of proliferating cell nuclear antigen (PCNA)
and actin, as a loading control. c Representative images of cells treated
as described and stained with crystal violet. d BrdU incorporation of
cells treated with enoxacin relative to control-treated cells. e Repre-
sentative images from a wound healing assay 0 and 14 h after
scratching. f Quantification of invasion rates. Left: representative
images of the lower chamber (invading cells). Right: cell invasion
rates relative to control-treated cells. g Immunoblot for fibronectin, N-
cadherin, ZEB1, and TWIST1. Values represent mean ± SD (n= 3).
*p < 0.05; **p < 0.01; ***p < 0.001
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In loss- or gain-of-function experiments, we observed
that DICER1 suppress cell aggressiveness (Fig. 8). Our
data are in contrast to a report showing that DICER1
overexpression positively regulates thyroid cell prolifera-
tion [40], but are in agreement with the observation that
Dicer1 knockout in embryonic thyroid results in a marked
increase of proliferation [21]. In addition, the extensive
analysis of TCGA data and our work herein strongly sup-


















Fig. 8 Summary of established DICER1-miRNA regulatory network
in thyroid cancer. Overexpressed (oncogenic) miRNAs in thyroid
cancer target DICER1. miR-146b (bold) directly binds to DICER1 3′
UTR; other miRNAs (grey) have a predicted biding site in DICER1 3′
UTR. Also, DICER1 upregulates tumor suppressor miRNAs, which in
turn inhibit proliferation, migration, invasion, and EMT. This effect
can be phenocopied when increasing the DICER1 complex activity
with the small-molecule enoxacin. The arrows denote induction and

















































































































Fig. 7 Enoxacin impairs
established human orthotopic
thyroid tumor growth and
decreases the expression of
EMT-related genes in vivo.
a–c Cal62-luc cells were
injected into the right thyroid
lobe. After the orthotopic model
was established, enoxacin or
vehicle was administered
intraperitoneally. a Left: the
image shows the endpoint (day
28) bioluminescent signal of the
tumors imaged with the IVIS-
Lumina II Imaging System.
Right: tumor radiance
quantification at the indicated
time points in mice from
treatment onset with enoxacin
(blue) or vehicle (green). b RNA
was obtained from the tumors
and miRNA expression levels
were determined. Shown are the
relative intratumoral levels of
miR-30a-5p, miR-146b-5p,
miR-221-3p, mIR-100-5p, miR-
21-5p, miR-30-5p, and miR-
204-5p. c Immunoblot of
intratumoral expression of
fibronectin, N-cadherin, and
PCNA in enoxacin- or vehicle-
treated mice. Values represent
mean ± SEM. *p < 0.05; n.s.
non-significant
5496 J. Ramírez-Moya et al.
We have demonstrated that global miRNA down-
regulation induced by DICER1 silencing promotes thyroid
cell aggressiveness. Notably, thyroid cancer progression
leads to fewer upregulated and more downregulated
miRNAs [12, 13]. This observation is consistent with the
hypothesis that the biogenesis machinery breaks down as
the tumor moves towards a more aggressive stage. That an
aggressive tumoral behavior becomes manifest after the
general downregulation of miRNAs points to an important
contribution of this process to the aggressive phenotype,
including the downregulation of tumor suppressor miRNAs.
This is supported by our data in DICER1-silenced cells
where the expression of tumor suppressors miR-30a and
miR-100 recover the normal thyroid phenotype.
It is important to find strategies to restore global miRNA
expression as a potential therapy in thyroid tumors.
Regarding the restoration of miRNAs with tumor sup-
pressor roles, few examples have been reported, but it is
reasonable to believe that restoring global miRNA levels
could have a therapeutic effect. Along this line, we used the
small-molecule enoxacin to enhance the production of
miRNAs, observing that this molecule reduces cell
aggressiveness in vitro and tumor growth in vivo without
signs of toxicity in animals [24]. The finding that enoxacin
treatment of non-transformed thyroid cells had less effect
than in tumoral cells suggests that this inductor of miRNA
biogenesis has a more specific action in tumoral thyroid
cells. In addition, we provide evidence that activating
miRNA biogenesis is a potentially important step towards
the application of miRNA-based therapy for the treatment
of thyroid cancer. This therapy is promising in other
pathologies [41].
In summary, our work reveals some key aspects on the
regulation and function of DICER1 in thyroid cancer.
Paradoxically, DICER1 is downregulated in thyroid cancer
through the upregulation of targeting miRNAs, particularly
miR-146b. DICER1 repression functionally leads to global
downregulation of the miRNA network, inducing increased
malignancy. Our data may have important clinical implica-
tions as DICER1 may convey prognostic information and,
more importantly, point to a potential therapeutic approach
based on the restoration of global miRNA levels via the
DICER1 pathway or using DICER1-targeting miRNA
inhibitors in patients with thyroid and other cancers.
Material and methods
Bioinformatic predictions
The TCGA database was queried to assess correlations
between mRNA and miRNA levels and clinical features.
Firebrowse (http://firebrowse.org) was used to analyze
DICER1 mRNA levels in different tumor types. The
cBioPortal (http://www.cbioportal.org) and the Cancer
Regulome Explorer (http://explorer.cancerregulome.org)
data portals were used to obtain the correlations using the
thyroid carcinoma dataset (THCA). The miRanda algorithm
(http://www.miRNAs.org) was used to predict hypothetical
associations between miRNAss and mRNAs.
Patients
Samples of PTC tumors and contralateral normal thyroid
tissue from the same patients (n= 7) were collected at the
Biobank of the Hospital Universitario La Paz (Madrid,
Spain). A summary of the main clinical characteristics of
the patients is included in Table SI. Written informed
consent was obtained from all the patients in accordance
with the protocols approved by the local ethics committee.
RNA quantification
RNA was extracted using TRIzol (Invitrogen). RT-PCR and
qRT-PCR were performed as described in Supplementary
Materials and Methods. The primer sequences used in this
study are listed in Table SII.
Cell culture and transfection
The human thyroid cancer cell lines of PTC (BCPAP and
TPC1) and ATC (Ocut2, Ktc2, Cal62, T235, Hth83, Hth74,
and SW1736) were cultured as described [42]. Rat PCC13
cells [43] and the human primary thyroid follicular cell line
Nthy-ori 3-1 [22], derived from normal thyroid tissue, were
cultured as described. Stable cell lines, transfections, and
Luciferase activity were performed as described in Sup-
plementary Materials and Methods.
Plasmids, constructs, and siRNA
The DICER1 expression vector was kindly provided by Dr
Richard Gregory (Boston Children’s Hospital, Boston) [44].
The pCMV2-miR30a vector was a gift from Dr. Bryan
Cullen (Addgene plasmid #20670) [45] and the pIS-
DICER1 long UTR was a gift from Dr David Bartel
(Addgene plasmid #21649) [46]. This construct was mutated
in the miR-146b binding site by site-directed mutagenesis as
described in Supplementary Material and Methods.
The luciferase and GFP-expressing vector, CMV-Firefly
luc-IRES-EGFP, was constructed by Dr. J. Bravo (IQAC-
CSIC), and the Cal62 human tumoral thyroid cell line stably
expressing this vector (Cal62-Luc) was generated by Dr.
Eugenia Mato (IB, Sant Pau).
The pre-miR-146b construct was previously cloned into
a pEGP expression vector (Cell Biolabs) [22]. The pre-miR-
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100 miRNAs were amplified from genomic DNA using the
follow primers: 5′-TCGAACGCGTTCCACCTCAGCCC
CCTTTTC-3′ (forward) and 5′-TCGAGAGCTCTGGGA
CGAAGTCCTTTCCATTT-3′ (reverese) and cloned into
the pEGP-miR expression vector. DICER1 siRNA was
purchased from Thermo Fisher (Silencer® Select Pre-
Designed siRNA Dicer1, s23754).
Protein extraction, western blotting, and
immunohistochemistry
Cells were lysed and proteins extracted as described [22].
Western blotting and immunohistochemistry procedures are
detailed in Supplementary Materials and Methods.
Cell proliferation assays
Proliferation was determined by proliferating cell nuclear
antigen (PCNA) expression, crystal violet staining and
bromodeoxyuridine (BrdU) incorporation, and measured as
described [22, 42]. Full details are in Supplementary
Materials and Methods.
Migration and invasion assays
Wound healing and cell invasion assays were performed as
described [22], and as detailed in Supplementary Materials
and Methods.
Enoxacin treatment in vitro
To stimulate miRNA expression, cells were treated with
enoxacin, sodium salt (EMDMillipore Corp.; cat. no. 557305)
at 40 µg/mL diluted in PBS with 5% DMSO, for 5 days [24].
In vivo studies
Animal experimentation was performed in compliance with
the European Community Law (86/609/EEC) and the
Spanish law (R.D. 1201/2005), with the approval of the
ethics committee of the Consejo Superior de Investiga-
ciones Científicas (CSIC, Spain).
Xenograft models have been extensively described pre-
viously in our previous study [22]. Orthotopic implantation
was performed as described in Supplementary Materials and
Methods.
Statistical analysis
Results are expressed as the mean ± SD of at least three
different experiments performed in triplicate. Results from
the in vivo studies and patient analysis are expressed as the
mean ± SEM. Statistical significance was determined by
Student’s t-test analysis (two-tailed) and differences were
considered significant at a P-value < 0.05.
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